Search

everythinglearnresearchcommunity

for

Search:↓

The book is a valuable resource for understanding hair and scalp problems but could be updated with more information on certain conditions.

Eating a balanced diet with specific nutrients can help manage menopause symptoms and prevent related health issues.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.

Manage women's cholesterol with diet, exercise, and careful treatment choices, especially during pregnancy, PCOS, and menopause.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

Young women with diffuse hair loss may have low SHBG levels, which could lead to more active testosterone and contribute to their hair loss.

The conclusion is that while oral contraceptive pills are effective for PCOS-related high androgen levels, new treatments with fewer side effects are needed.

The conclusion is that managing cholesterol is important for women, especially during pregnancy, breastfeeding, and with PCOS, and involves regular screening and careful treatment choices.

Women with PCOS may take longer to get pregnant but can have a normal family size, and should manage their overall health to reduce long-term health risks.

Menopause significantly reduces skin collagen, leading to thinner, less elastic skin, and hormone replacement may help but requires careful consideration.

Menopause and aging can affect women's quality of life and sexuality, but hormone therapies may help alleviate these issues.

A team approach is crucial for managing PCOS, with dermatologists playing a key role.

Menstrual disorders are common in adolescents and can be influenced by weight, activity, and health issues, requiring careful evaluation and more research for effective treatment.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.

Birth control pills increase the risk of blood clots, especially within the first year and with certain types.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Polycystic Ovary Syndrome likely starts in childhood and may be genetic and influenced by early hormone exposure.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Women with keloid scars often have acne and hair loss, especially those with "true" keloids, indicating a possible hormonal imbalance.

Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.

Estradiol-rich plasma can increase hair density faster and more effectively in male pattern baldness treatment than regular plasma.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

The document concludes that skin aging in women can be caused by UV exposure and hormonal changes, and treatments like hormone replacement therapy and various skin therapies can help.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.